Frontlight ResearchEarly access
Taking peoplePhase 3
Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France10 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 50 people, planned
- Started
- 4 Jun 2024
- Expected to end
- 4 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- ANAKINRA
- Record updated
- 25 June 2025
Who can take part
- Age
- 6 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Age >= 6 years old with no upper limit
- Proven FMF according to Livneh international criteria and 2 non ambiguous MEFV mutations
- Colchicine resistance defined as persistent FMF attack despite the maximum daily posology of colchicine (average one or more attacks per month over a 3-months period); FMF Attack is defined by:
- Arthritis or
- Chest pain or
- Abdominal pain or
- Myalgia or
- Erysipelas-like skin lesion Duration of episodes 1-4 days
- Patient refusing daily anakinra injections-
- Patients covered at 100% by the health insurance (ALD)
- Patient who do not have biological inflammation between attacks
- Written informed consent of the patients and or his legal representatives
Who cannot take part
- Infection requiring treatment with intravenous antibiotics within 2 weeks prior to inclusion
- Ongoing chronic treatment with anti IL1 biotherapy since at least 3 months
- Evidence of active tuberculosis
- History of recurrent infection (Need more than 4 courses of antibiotic treatment per year (in children) or more >2 times per year (in adults), experience pneumonia twice over any time or >3 bacterial sinusitis in 1 year)
- Absence of active or latent tuberculosis (no tuberculosis sign on chest X-ray and a negative quantiferon)
- Contraindication to anakinra (Hypersensitivity to the active substance or to any of the excipients (Citric acid, anhydrous Sodium chloride, Disodium edetate dehydrate, Polysorbate 80, Sodium hydroxide, Water for injections ) or to E. coli derived proteins
- Patients with neutropenia (ANC <1.5 x 10\^9/l)
- Inability to provide informed consent
- Pregnant women
- Women in labor and nursing mothers
- Patients in emergency situations and people hospitalized without consent
- No health care insurance
- Contraindication to colchicine
- Patient participating in another interventional clinical trial
- Patient deprived of liberty
- Patient under guardianship or curatorship
- Patient under court protection; Randomization criteria :
- Negative pregnancy test
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy on clinical symptoms in case of FMF attack among FMF patients resistant to Colchicine of
Read full original descriptionShow less
* on demand anakinra treatment (100 mg/d from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) associated with daily colchicine. * compared to analgesic associated with daily colchicine in patients refusing continuous anti-IL-1 treatment.
The 2 groups in the trial
- ANAKINRA on DemandTreatment being tested
On demand Anakinra 100 mg/j from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) + colchicine + on demand analgesics
Treatment: ANAKINRA
- Standard of CareNo study treatment, for comparison
Usual analgesics + colchicine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 25 June 2025